Pharmacological Effects of Diosgenin in Cancer and Disease Management

Diosgenin is a naturally occurring steroidal sapogenin found predominantly in species of Dioscorea, Trigonella and Smilax. It serves not only as a precursor for the synthesis of various steroidal drugs but also exhibits a broad spectrum of bioactivities relevant to cancer and chronic disease management. In oncology, diosgenin exerts anti-proliferative effects by inducing cell cycle arrest at G2/M or S phases, promoting mitochondrial-mediated apoptosis through Bcl-2 family modulation and activating caspase cascades. It also attenuates metastatic potential via suppression of matrix metalloproteinases and inhibition of key signalling axes such as PI3K/Akt, MAPK and NF-κB. Beyond its anticancer profile, diosgenin demonstrates anti-inflammatory and antioxidant actions that underpin its efficacy in metabolic disorders, atherosclerosis and neurodegeneration. Preclinical studies support its ability to ameliorate hyperlipidaemia, improve insulin sensitivity and protect against ischaemic injury in neuronal models. Early clinical investigations attest to a favourable safety profile and hint at benefits for cognitive function and menopausal symptoms. Advances in formulation—ranging from nano-encapsulation to structural analogues—have sought to enhance solubility, bioavailability and target engagement. Collectively, these findings underscore diosgenin’s versatility as both a lead compound for pharmaceutical development and a dietary adjuvant for holistic disease management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Effects of Diosgenin in Cancer and Disease Management publication trend

The graph below shows the total number of articles in pharmacological effects of diosgenin in cancer and disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Sapogenin: A steroidal aglycone derived from saponin glycosides, serving as the core bioactive moiety in diosgenin.

Apoptosis: Programmed cell death characterised by caspase activation, DNA fragmentation and membrane blebbing, essential for eliminating malignant cells.

PI3K/Akt pathway: A central intracellular signalling cascade regulating cell survival, proliferation and metabolism, often dysregulated in cancer.

Matrix metalloproteinases (MMPs): A family of proteolytic enzymes that degrade extracellular matrix components, facilitating tumour invasion and metastasis.

Bioavailability: The proportion of an administered compound that reaches systemic circulation in an active form, critical for therapeutic efficacy.

References

1. Diosgenin: Chemistry, extraction, quantification and health benefits. Food Chemistry Advances (2023).
2. Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. Nutrients (2018).
3. Diosgenin, a Steroidal Saponin, Inhibits Migration and Invasion of Human Prostate Cancer PC-3 Cells by Reducing Matrix Metalloproteinases Expression. PLOS ONE (2011).
4. Therapeutic Potential of Diosgenin and Its Major Derivatives against Neurological Diseases: Recent Advances. Oxidative Medicine and Cellular Longevity (2020).
5. Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives. Oxidative Medicine and Cellular Longevity (2022).
6. Induction of G2/M Phase Arrest by Diosgenin via Activation of Chk1 Kinase and Cdc25C Regulatory Pathways to Promote Apoptosis in Human Breast Cancer Cells. International Journal of Molecular Sciences (2019).